EMA/719274/2016

European Medicines Agency decision

P/0310/2016

of 4 November 2016

on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0310/2016

of 4 November 2016

on the acceptance of a modification of an agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), (EMEA-000713-PIP02-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/242/2010 issued on 16 November 2010, the decision P/0036/2012 issued on 13 February 2012, the decision P/0103/2013 issued on 30 April 2013 and the decision P/0081/2015 issued on 10 April 2015,

Having regard to the application submitted by CTI Life Sciences Limited on 27 July 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pixantrone (dimaleate) (Pixuvri), powder for concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to CTI Life Sciences Limited, Highlands House, Basingstoke Road, Spencers Wood, Reading, RG7 1NT - Berkshire, United Kingdom.

EMA/PDCO/527374/2016
London, 14 October 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000713-PIP02-10-M04

Scope of the application

Active substance(s):

Pixantrone (dimaleate)

Invented name:

Pixuvri

Condition(s):

Treatment of non-Hodgkin lymphoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CTI Life Sciences Limited

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, CTI Life Sciences Limited submitted to the European Medicines Agency on 27 July 2016 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/242/2010 issued on 16 November 2010, the decision P/0036/2012 issued on 13 February 2012, the decision P/0103/2013 issued on 30 April 2013 and the decision P/0081/2015 issued on 10 April 2015.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 August 2016.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

Waiver

1.1. Condition:

Treatment of non-Hodgkin lymphoma

The waiver applies to:

- infants from birth to less than 6 months of age;
- for powder for concentrate for solution for infusion, for intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of non-Hodgkin lymphoma

2.1.1. Indication(s) targeted by the PIP

Pixantrone (dimaleate) in combination therapy for the treatment of non-Hodgkin lymphoma in paediatric patients aged 5 years to less than 18 years

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	3	**Study 1:** Mice cardiotoxicity study **Study 2:** Toxicokinetics of sudden death mice **Study 3:** Evaluation of pixantrone efficacy in vivo xenograft models of paediatric solid tumours
Clinical studies	3	**Study 4:** Open-label, non-controlled, multi-centre, dose-escalation trial to evaluate pharmacokinetics, safety and tolerability of pixantrone in children from 6 months to less than 18 years (and young adults) with a lymphoid malignancy or a solid malignant

		tumour **Study 5:** Open-label, non-controlled trial to evaluate pharmacokinetics, safety and activity of pixantrone in a combination chemotherapy regimen in children from 5 years to less than 18 years with non-Hodgkin lymphoma and / or malignant solid tumours **Study 6:** Open-label, randomised, active-controlled, multi-centre trial to evaluate safety and efficacy of pixantrone in children from 5 years to less than 18 years with non-Hodgkin lymphoma and / or malignant solid tumours
Extrapolation, modelling and simulation studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of non-Hodgkin lymphoma

Authorised indication(s):

- Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

Authorised pharmaceutical form(s):

Powder for concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use